

# Rajेशha Rupaimoole

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4691655/publications.pdf>

Version: 2024-02-01

62  
papers

9,567  
citations

70961

41  
h-index

114278

63  
g-index

63  
all docs

63  
docs citations

63  
times ranked

19124  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 203-222.	21.5	3,558
2	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	13.9	651
3	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. <i>Cancer Discovery</i> , 2016, 6, 235-246.	7.7	554
4	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013, 4, 2427.	5.8	363
5	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. <i>Cancer Cell</i> , 2013, 23, 186-199.	7.7	340
6	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , 2014, 10, 728.	3.2	255
7	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	7.7	252
8	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. <i>Nature Communications</i> , 2014, 5, 5203.	5.8	195
9	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017, 8, 310.	5.8	169
10	Autocrine Effects of Tumor-Derived Complement. <i>Cell Reports</i> , 2014, 6, 1085-1095.	2.9	164
11	Role of Focal Adhesion Kinase in Regulating YAP1-Mediated Paclitaxel Resistance in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1485-1495.	3.0	151
12	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014, 5, 5202.	5.8	151
13	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018, 9, 2923.	5.8	151
14	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	3.2	122
15	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 159-172.	3.6	115
16	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015, 13, 2395-2402.	2.9	105
17	2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014, 5, 3459.	5.8	103
18	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	102

#	ARTICLE	IF	CITATIONS
19	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896.	3.9	101
20	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	5.8	100
21	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	7.7	94
22	miR-506 inhibits multiple targets in the epithelial-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. <i>Journal of Pathology</i> , 2015, 235, 25-36.	2.1	94
23	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , 2016, 35, 4312-4320.	2.6	83
24	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	82
25	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3280-3288.	3.2	80
26	Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5331-5336.	3.3	79
27	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2876-2885.	1.9	77
28	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , 2016, 35, 2390-2397.	2.6	71
29	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1713-1724.	3.2	69
30	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018, 78, 3233-3242.	0.4	69
31	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	3.2	67
32	Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma. <i>Neoplasia</i> , 2013, 15, 502-515.	2.3	66
33	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. <i>Journal of Immunology</i> , 2016, 196, 1412-1418.	0.4	66
34	A new method for stranded whole transcriptome RNA-seq. <i>Methods</i> , 2013, 63, 126-134.	1.9	59
35	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.4	59
36	ATP11B mediates platinum resistance in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2119-2130.	3.9	56

#	ARTICLE	IF	CITATIONS
37	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	3.0	51
38	Role of Platelet-Derived Tgff <sup>21</sup> in the Progression of Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5611-5621.	3.2	51
39	The ZNF304-integrin axis protects against anoikis in cancer. Nature Communications, 2015, 6, 7351.	5.8	48
40	Pan-cancer genomic analysis links 3â€™UTR DNA methylation with increased gene expression in T cells. EBioMedicine, 2019, 43, 127-137.	2.7	48
41	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell, 2014, 26, 863-879.	7.7	46
42	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	2.9	43
43	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics, 2016, 15, 1344-1352.	1.9	41
44	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene, 2016, 35, 691-701.	2.6	40
45	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research, 2015, 21, 3286-3297.	3.2	37
46	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 1061-1067.	1.5	34
47	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	2.9	32
48	Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 1750-1757.	1.9	31
49	Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib. Clinical Cancer Research, 2014, 20, 1846-1855.	3.2	25
50	Developing hyperpolarized silicon particles for <i>in vivo</i> MRI targeting of ovarian cancer. Journal of Medical Imaging, 2016, 3, 036001.	0.8	24
51	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 2018, 9, 25115-25126.	0.8	24
52	<i>PRKRA</i> /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	1.9	23
53	<i>PTEN</i> Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics, 2015, 14, 1466-1475.	1.9	20
54	C-terminal fragment of transforming growth factor beta-induced protein (TGFB1p) is required for apoptosis in human osteosarcoma cells. Matrix Biology, 2009, 28, 347-353.	1.5	19

#	ARTICLE	IF	CITATIONS
55	A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. <i>IScience</i> , 2020, 23, 100878.	1.9	13
56	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016, 1, e87754.	2.3	11
57	A role for miR-34 in colon cancer stem cell homeostasis. <i>Stem Cell Investigation</i> , 2016, 3, 42-42.	1.3	9
58	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	9
59	Macrophage TGF- $\beta$ 1 and the Proapoptotic Extracellular Matrix Protein BIGH3 Induce Renal Cell Apoptosis in Prediabetic and Diabetic Conditions. <i>International Journal of Clinical Medicine</i> , 2016, 07, 496-510.	0.1	8
60	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015, 1, 15001.	1.4	3
61	Complement Component 3 (C3) Is Transcriptionally Regulated By TWIST1. <i>Blood</i> , 2013, 122, 1046-1046.	0.6	1
62	MicroRNA therapeutics: principles, expectations, and challenges. <i>Chinese Journal of Cancer</i> , 2011, 30, 368-370.	4.9	1